XERIS BIOPHARMA HOLDINGS, INC. Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share data) 2021 2020 Product revenues, net $ 49,280 $ 20,155 Royalty, contract and other revenue 310 280 Total revenue 49,590 20,435 Costs and expenses: Cost of goods sold, excluding amortization of intangible assets 13,318 9,328 Research and development 25,160 20,921 Selling, general and administrative 125,718 73,732 Amortization of intangible assets 550 — Total costs and expenses 164,746 103,981 Loss from operations (115,156) (83,546) Other income (expense): Interest and other income 313 2,965 Interest expense (7,180) (10,660) Change in fair value of warrants (702) (9) Total other expense (7,569) (7,704) Net loss before benefit from income taxes (122,725) (91,250) Benefit from income taxes — 110 Net loss $ (122,725) $ (91,140) Other comprehensive loss, net of tax: Unrealized losses on investments (38) (10) Foreign currency translation adjustments 1 (27) Comprehensive loss $ (122,762) $ (91,177) Net loss per common share - basic and diluted $ (1.55) $ (2.14) Weighted average common shares outstanding - basic and diluted 79,027,062 42,642,901 Years Ended December 31, See accompanying notes to consolidated financial statements. 91
RkJQdWJsaXNoZXIy NTIzOTM0